Evidence map›Paper›PMID 25377794›Full record

ReviewMolecular neurobiology2015

From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Opportunities for 5-HT3 Receptor Antagonists.

Gohar Fakhfouri, Kazem Mousavizadeh, Sharam Ejtemaei Mehr, Ahmad Reza Dehpour, Mohammad Reza Zirak, Jean-Eric Ghia, Reza Rahimian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. The Concise Guide to PHARMACOLOGY 2023/24: Ion channels.British journal of pharmacology · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Tapping into 5-HTInternational journal of molecular sciences · 2021
    Review
  12. Article
  13. Article
  14. Involvement of 5-Serotonin and SubstanceFrontiers in pharmacology · 2021
    Article
  15. Contribution of Hippocampal 5-HTCellular and molecular neurobiology · 2017
    Article
  16. Review
  17. The serotonergic system and cognitive function.Translational neuroscience · 2016
    Review
  18. Serotonin, neural markers, and memory.Frontiers in pharmacology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Gohar FakhfouriDepartment of Psychiatry and Neuroscience, Université Laval, Québec, QC, Canada.
Kazem MousavizadehCellular and Molecular Research Center and Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Sharam Ejtemaei MehrDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P. O. Box 13145-784, Tehran, Iran.
Ahmad Reza DehpourDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P. O. Box 13145-784, Tehran, Iran.
Mohammad Reza ZirakDepartment of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Jean-Eric GhiaDepartment of Immunology and Internal Medicine Section of Gastroenterology, Faculty of Medicine, University of Manitoba, Manitoba, Winnipeg, Canada.
Reza RahimianDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P. O. Box 13145-784, Tehran, Iran. rahimian78@gmail.com.
Tehran University of Medical Sciences · IRInstitut Universitaire en Santé Mentale de Québec · CAIran University of Medical Sciences · IRMashhad University of Medical Sciences · IRUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5-HT3 receptor antagonists are extensively used as efficacious agents in counteracting chemotherapy-induced emesis. Recent investigations have shed light on other potential effects (analgesic, anxiolytic, and anti-psychotic). Some studies have reported neuroprotective properties for the 5-HT3 receptor antagonists in vitro and in vivo. When administered to Aβ-challenged rat cortical neurons, 5-HT3 receptor antagonists substantially abated apoptosis, elevation of cytosolic Ca(2), glutamate release, reactive oxygen species (ROS) generation, and caspase-3 activity. In addition, in vivo studies show that 5-HT3 receptor antagonists possess, alongside their anti-emetic effects, notable immunomodulatory properties in CNS. We found that pretreatment with tropisetron significantly improved neurological deficits and diminished leukocyte transmigration into the brain, TNF-α level, and brain infarction in a murine model of embolic stroke. Our recent investigation revealed that tropisetron protects against Aβ-induced neurotoxicity in vivo through both 5-HT3 receptor-dependent and -independent pathways. Tropisetron, in vitro, was found to be an efficacious inhibitor of the signaling pathway leading to the activation of pro-inflammatory NF-κB, a transcription factor pivotal to the upregulation of several neuroinflammatory mediators in brain. This mini review summarizes novel evidence concerning effects of 5-HT3 antagonists and their possible mechanisms of action in ameliorating neurodegenerative diseases including Alzheimer, multiple sclerosis, and stroke. Further, we discuss some newly synthesized 5-HT3 receptor antagonists with dual properties of 5-HT3 receptor blockade/alpha-7 nicotinic receptor activator and their potential in management of memory impairment. Since 5-HT3 receptor antagonists possess a large therapeutic window, they can constitute a scaffold for design and synthesis of new neuroprotective medications.

Indexed as

Drug TherapyAnimalsHumansIndolesMultiple SclerosisReceptors, Serotonin, 5-HT3Serotonin 5-HT3 Receptor AntagonistsTropisetronVomitingIndolesReceptors, Serotonin, 5-HT3Serotonin 5-HT3 Receptor AntagonistsTropisetron5-HT3 receptor antagonistAnti-inflammatoryNeurodegenerationNeuroinflammationNeuroprotective

Identifiers

PMID25377794
OpenAlexW2026083831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.